{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T20:23:49Z","timestamp":1784492629497,"version":"3.55.0"},"reference-count":22,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,9,3]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence of severe immune-related hepatitis (irHepatitis) Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4 under combination therapy with ipilimumab and nivolumab ranges from 15% to 20%. Current clinical guidelines recommend initiating treatment with systemic corticosteroids, followed by second-line immunosuppressants such as mycophenolate mofetil. In contrast, the use of the tumor necrosis factor-\u03b1 antibody infliximab\u2014commonly administered for other immune-related adverse events such as colitis\u2014is generally not recommended for irHepatitis. A recent single-center study, however, reported the use of infliximab for steroid-refractory irHepatitis in 10 patients without signs of infliximab-associated hepatotoxicity and overall favorable efficacy.<\/jats:p>\n                    <jats:p>This multicenter retrospective analysis aimed to evaluate the safety and efficacy of infliximab in patients with steroid-refractory irHepatitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 28 patients with advanced cutaneous melanoma and irHepatitis during immune checkpoint inhibitor (ICI) therapy were included from five university hospitals in Germany and one in Belgium. Of these, 27 patients were in American Joint Committee on Cancer stage IV (8th edition).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients received ipilimumab plus nivolumab. The Eastern Cooperative Oncology Group performance status was 0 in 75.0% of patients, and nearly all (27\/28) developed severe irHepatitis of CTCAE grade 3 or 4 (V.5.0). The median time to onset of irHepatitis was 46 days after first ICI administration. 96.4% of patients were initially treated with systemic corticosteroids. The median interval between onset of irHepatitis and the first dose of infliximab was 23 days. Infliximab was administered intravenously at a dose of 5\u2009mg\/kg. 22 patients received one dose, while 6 patients received two doses. In 82.1% of patients, corticosteroids were tapered to less than 5\u2009mg prednisolone equivalent within a median period of 75 days. Clinical remission for irHepatitis (\u2264CTCAE grade 1) was achieved in 92.9% of patients and was reached after a median time of 21 days following the first infliximab administration. During a median follow-up of 349 days, no deaths or drug-induced liver injury attributable to infliximab were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this retrospective analysis, infliximab appeared to be effective and safe for the treatment of steroid-refractory irHepatitis, with no evidence of hepatotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-013038","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T05:25:29Z","timestamp":1758691529000},"page":"e013038","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis"],"prefix":"10.1136","volume":"13","author":[{"given":"Kim Nikola","family":"Oliva","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9649-3423","authenticated-orcid":false,"given":"Lisa","family":"Arnold","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany"},{"name":"SERIO\u2014Side Effect Registry Immuno-Oncology, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-8017","authenticated-orcid":false,"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany"},{"name":"SERIO\u2014Side Effect Registry Immuno-Oncology, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"},{"name":"Skin Cancer Center, National Center for Tumor Diseases and University Cancer Center Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"},{"name":"Skin Cancer Center, National Center for Tumor Diseases and University Cancer Center Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-3195","authenticated-orcid":false,"given":"Katharina","family":"Meier","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Huynh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Schlaak","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Charit\u00e9 - Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Gesierich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Julius-Maximilians-Universit\u00e4t W\u00fcrzburg, University Hospital, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dirven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Universitair Ziekenhuis Brussel (UZ Brussel)\/Vrije Universiteit Brussel (VUB), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Trojan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kleemann","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8859-4103","authenticated-orcid":false,"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"2026052108451930000_13.9.e013038.1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.02.041","article-title":"Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"130","author":"Romanski","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026052108451930000_13.9.e013038.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2026052108451930000_13.9.e013038.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2026052108451930000_13.9.e013038.4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007409","article-title":"Corticosteroid-resistant immune-related adverse events: a systematic review","volume":"12","author":"Daetwyler","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026052108451930000_13.9.e013038.5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jhep.2021.08.024","article-title":"Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment","volume":"76","author":"Bj\u00f6rnsson","year":"2022","journal-title":"J Hepatol"},{"key":"2026052108451930000_13.9.e013038.6","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.3390\/curroncol28030201","article-title":"Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events","volume":"28","author":"Araujo","year":"2021","journal-title":"Curr Oncol"},{"key":"2026052108451930000_13.9.e013038.7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008074","article-title":"Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids","volume":"12","author":"Burri","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026052108451930000_13.9.e013038.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"2026052108451930000_13.9.e013038.9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jhep.2014.01.032","article-title":"Anti-TNF-induced autoimmune hepatitis","volume":"61","author":"Borman","year":"2014","journal-title":"J Hepatol"},{"key":"2026052108451930000_13.9.e013038.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.010"},{"key":"2026052108451930000_13.9.e013038.11","doi-asserted-by":"crossref","first-page":"114028","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"Ruf","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026052108451930000_13.9.e013038.12","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0532-1","article-title":"Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab","volume":"7","author":"Zhang","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026052108451930000_13.9.e013038.13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jhepr.2019.02.001","article-title":"Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report","volume":"1","author":"Corrigan","year":"2019","journal-title":"JHEP Rep"},{"key":"2026052108451930000_13.9.e013038.14","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1200\/JCO.2024.42.16_suppl.12133","article-title":"Early combination with mycophenolate mofetil for immune-related hepatitis in patients with solid tumors treated with immune checkpoint inhibitors","volume":"42","author":"Igawa","year":"2024","journal-title":"JCO"},{"key":"2026052108451930000_13.9.e013038.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113313"},{"key":"2026052108451930000_13.9.e013038.16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1088741","article-title":"Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: A systematic review and meta-analysis","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"2026052108451930000_13.9.e013038.17","doi-asserted-by":"crossref","first-page":"114065","DOI":"10.1016\/j.ejca.2024.114065","article-title":"Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers","volume":"204","author":"Cariou","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026052108451930000_13.9.e013038.18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15215181","article-title":"Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response","volume":"15","author":"Parvathareddy","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026052108451930000_13.9.e013038.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2026052108451930000_13.9.e013038.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"2026052108451930000_13.9.e013038.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3322"},{"key":"2026052108451930000_13.9.e013038.22","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma","volume":"8","author":"van Not","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-013038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:45:34Z","timestamp":1779378334000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-013038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,23]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/jitc-2025-013038"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-013038","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}